Never trust the buybacks. It is often done to help insiders unload at high price.
biib is the most underperformed stock within the biotech sector
but when you are ready to buy i am ready to sell
somebody gotta buy my biotech holdings, eh?
trading rule = always capture green profits leaning on strength
rinse and repeat - repeat and rinse ... hehehehe
not today my friend 260 is gone
pre-market now 282
let's gooooo biogen
gotta capture green
from my 4 small biotech holdings
at top prices this morning = kapow
stock pulling back to 278 now is a concern
small biotech stocks not trading yet
gotta sell at market opening prices
let's hope so but i am more interested in stock price action
gotta rinse and repeat - i like biib because it is underperformed
and today she is a big lift to lala land along with the biotech sector
are u listening to conf call?.. they might have cure for MS with anti-lingo........................
stock pulls back from 288 to 280
gotta capture profit fast fast fast
=== Tecfidera, a multiple-sclerosis drug, got off to a strong start two years ago, but sales growth has waned of late. Third-quarter revenue from the drug was 6% above the second quarter, whose sequential growth as 7%. And in the first quarter, revenue fell 10% from the last quarter of 2014.
Biogen is scrapping several drug-development efforts as part of the retrenchment, including a late-stage effort looking at Tecfidera as a potential treatment for secondary progressive MS. That comes as Biogen this morning separately announced an unsuccessful late-stage study for its Tysabri MS drug involving secondary progressive MS.